This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The hypothesis is that short-term administration of a PPARy agonist (pioglitazone) will improve insulin resistance, inflammatory state and endothelial dysfunction in chronic kidney disease patients with advanced uremia.
Showing the most recent 10 out of 515 publications